The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

被引：15

作者：

Garcia, Christine ^{[1
]}

Ring, Kari L. ^{[1
]}

机构：

[1] Univ Virginia, Thorton Div Gynecol Oncol, Dept Obstet & Gynecol, 1215 Lee St, Charlottesville, VA 22902 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2018年 / 19卷 / 12期

关键词：

Programmed death ligand-1; Immunotherapy; Gynecologic cancer; Ovarian cancer; Endometrial cancer; Cervical cancer; TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; HUMAN-PAPILLOMAVIRUS; IMPROVED SURVIVAL; T-CELLS; ANTI-PD-L1; ANTIBODY; ANTITUMOR-ACTIVITY; OVARIAN-CARCINOMA; NEOANTIGEN LOAD; LYNCH SYNDROME;

D O I：

10.1007/s11864-018-0593-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion statementActivity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.

引用

页数：14

共 50 条

[1] The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Christine Garcia
Kari L. Ring
Current Treatment Options in Oncology, 2018, 19
[2] Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies
Ring, Kari L.
Pakish, Janelle
Jazaeri, Amir A.
CANCER JOURNAL, 2016, 22 (02) : 101 - 107
[3] The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
Marinelli, Oliviero
Annibali, Daniela
Aguzzi, Cristina
Tuyaerts, Sandra
Amant, Frederic
Morelli, Maria Beatrice
Santoni, Giorgio
Amantini, Consuelo
Maggi, Federica
Nabissi, Massimo
FRONTIERS IN ONCOLOGY, 2019, 9
[4] PD-1/PD-L1 checkpoint in hematological malignancies
Annibali, O.
Crescenzi, A.
Tomarchio, V.
Pagano, A.
Bianchi, A.
Grifoni, A.
Avvisati, G.
LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
[5] PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Post, Cathalijne C. B.
Westermann, Anneke M.
Bosse, Tjalling
Creutzberg, Carien L.
Kroep, Judith R.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 152
[6] Immune Checkpoint Inhibition in the Treatment of Gynecologic Cancer
Kristen Anderson
Ramez N. Eskander
Current Obstetrics and Gynecology Reports, 2018, 7 (1) : 6 - 19
[7] Immune Checkpoint Inhibition in the Treatment of Gynecologic Cancer
Anderson, Kristen
Eskander, Ramez N.
CURRENT OBSTETRICS AND GYNECOLOGY REPORTS, 2018, 7 (01): : 6 - 19
[8] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, Xiangjiao
Huang, Zhaoqin
Teng, Feifei
Xing, Ligang
Yu, Jinming
CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
[9] The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Kooshkaki, Omid
Derakhshani, Afshin
Safarpour, Hossein
Najafi, Souzan
Vahedi, Parviz
Brunetti, Oronzo
Torabi, Mitra
Lotfinejad, Parisa
Paradiso, Angelo Virgilio
Racanelli, Vito
Silvestris, Nicola
Baradaran, Behzad
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14) : 1 - 22
[10] The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy
Setordzi, Patience
Chang, Xing
Liu, Zi
Wu, Yingliang
Zuo, Daiying
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 895

← 1 2 3 4 5 →